Abstract
The cell cycle of eukaryotic cells is regulated by a family of protein kinases called cyclin-dependent kinases (Cdks). We have reported the identification and biological characterization of a highly potent, small-molecule pan-Cdk inhibitor, which inhibited Cdk1, 2, 4, 5, 6, and 9 with equal potency in the nM range. This compound inhibited multiple events in the cell cycle and induced cell death in human cancer cell lines as well as in peripheral blood or purified resting lymphocytes ex vivo. We describe the materials and methods to determine antitumor efficacy in vivo xenograft models. Pharmacodynamic marker assays that have been performed using tumors and normal tissues are explained. Moreover, we briefly describe methods for determining the effects of chemical Cdk inhibitors on peripheral blood cells or lymphocytes ex vivo.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Sherr CJ (1996) Cancer cell cycles. Science 274:1672–1677
Sherr CJ (2000) The Pezcoller lecture: cancer cell cycles revised. Cancer Res 60:3689–3695
Pines J (1995) Cyclins and cyclin-dependent kinases: theme and variations. Adv Cancer Res 66:181–212
Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501–1512
Pavletich NP (1999) Mechanism of cyclin-dependent kinase regulation: structures of cdks, their cyclin activators, and CIP and INK4 inhibitors. J Mol Biol 287:821–828
Koepp DM, Haper JW, Elledge SJ (1999) How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 97:431–434
Falco GD, Giordan A (1998) CDK9 (PITALRE): a multifunctional cdc2-related kinase. J Cell Physiol 177:501–506
Palancade B, Bensaude O (2003) Investigating RNA polymerase II carboxyl-terminal domain (CTD) phosphorylation. Eur J Biochem 270:3859–3870
Price DH (2000) P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol 20:2629–2634
Dhavan R, Tsai L-H (2001) A decade of CDK5. Nat Rev Mol Cell Biol 2:749–759
Lilja L, Yang S, Webb D et al (2001) Cyclin-dependent kinase 5 promotes insulin exocytosis. J Biol Chem 276:34199–34205
Hirai H, Takahashi-Suzuki I, Shimomura T et al (2011) Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo. Invest New Drugs 29:534–543
Kobayashi M, Takahashi-Suzuki I, Shimomura T et al (2011) Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor. Invest New Drugs 29:921–931
Hirai H, Shimomura T, Kobayashi M et al (2010) Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo. Cell Cycle 9:1590–1600
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Hirai, H., Nakatsuru, Y. (2016). Evaluating Chemical CDK Inhibitors as Cell Death Inducers. In: Orzáez, M., Sancho Medina, M., Pérez-Payá, E. (eds) Cyclin-Dependent Kinase (CDK) Inhibitors. Methods in Molecular Biology, vol 1336. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2926-9_14
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2926-9_14
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2925-2
Online ISBN: 978-1-4939-2926-9
eBook Packages: Springer Protocols